Medicine Man Technologies, Inc. New Team Member Takes Equity Stake in Company Through Direct Purchases Of Stock From Corporate Insider

DENVER, April 2, 2019 /PRNewswire/ -- Medicine Man Technologies, Inc. (OTCQX: MDCL) ("Medicine Man Technologies" or "Company"), a rapidly growing, vertically integrated cannabis operator, announced that one of its investors, Tigran Muradyan has joined the management team as Director of Products. In his position at Medicine Man Technologies, Mr. Muradyan will work closely with the executive management team in the development and execution of an array of products and services offered by Medicine Man Technologies, thus furthering the growth of the Company's revenue.

Medicine Man Technologies Inc. Logo (PRNewsfoto/Medicine Man Technologies Inc.)

Mr. Muradyan facilitated an investment of approximately $1 million in Medicine Man Technologies through the purchase of 600,000 common stock shares from Joshua Haupt, Medicine Man Technologies' Chief Revenue Officer. He personally purchased 400,000 of those shares.

Mr. Muradyan brings a wealth of sales experience with him to Medicine Man Technologies. He is an experienced business development officer with extensive expertise in the financial services industry and knowledge within securities, investment advisory, management, and securities regulation. Most recently he served as an external financial wholesaler, raising $530 million throughout 2017 and 2018.

"During the span of his career, Tigran has distinguished himself as a top industry advisor, critical thinker, and top sales executive, demonstrating his ability to lead conversations about industry trends, challenges, and opportunities," said Joe Puglise, Chief Operating Officer of Medicine Man Technologies. "His deep experience will be instrumental in the development of our next generation of products and services as a vertically integrated cannabis brand and operator."

Mr. Muradyan started his career in banking and later moved to investments, obtaining his series 7, 63, and 65 licenses to become a stockbroker. He recently served as Business Development Officer at AssetMark, an investment adviser and a leading independent provider of innovative investment and consulting solutions serving financial advisors. Prior to that he was an External Senior Regional Business Consultant at Curian Capital, a registered investment advisor providing wealth management platforms to its financial professionals.

About Medicine Man Technologies
Medicine Man Technologies is a fully integrated operator in the cannabis industry, offering consulting, retail pharma-grade products, and turnkey solutions for cannabis cultivators for over a decade. Medicine Man Technologies is leveraging its expertise and intellectual property to vertically integrate retail, cultivation, formulation, and distribution operations. The Company's client portfolio includes active and past clients in 18 states and seven countries. 

Forward-Looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified. Consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise.

Investor Relations Contact:


Cision View original content to download multimedia:

SOURCE Medicine Man Technologies Inc.